Library coverage
Our starting list.
A growing reference.
124 compound, combination and related-name topics. Review labels distinguish draft evidence summaries from topics awaiting research.
Supplier catalogs helped identify initial topics. Scientific summaries and supplier evaluations are separate editorial work. Different molecular modifications and uncertain names remain explicitly distinguished.
Search the library · Blends versus stacks
Download the encyclopedia topic list (CSV)
Topics to explore
- 5-Amino-1MQ — Draft evidence summary
- ABP-7 — Draft context overview
- ACE-031 — Draft evidence summary
- Acetyl Hexapeptide-3 (Argireline) — Draft evidence summary
- Adamax — Draft context overview
- Adipotide (FTPP) — Draft evidence summary
- AHK-Cu — Draft evidence summary
- AICAR — Draft evidence summary
- AOD-9604 — Draft evidence summary
- ARA-290 — Draft evidence summary
- B7-33 — Draft evidence summary
- BPC-157 — Draft evidence summary
- Bronchogen — Draft evidence summary
- Cardiogen — Draft evidence summary
- Cartalax — Draft context overview
- Chonluten — Draft evidence summary
- CJC-1295 — Draft evidence summary
- CJC-1295 & GHRP-2 Blend — Draft combination overview
- CJC-1295 & GHRP-6 Blend — Draft combination overview
- CJC-1295 & Ipamorelin Blend — Draft combination overview
- Cortagen — Draft evidence summary
- Crystagen — Draft evidence summary
- Decapeptide-12 — Draft evidence summary
- DSIP — Draft evidence summary
- Epithalon — Draft evidence summary
- Follistatin-344 — Draft evidence summary
- FOXO4-DRI — Draft evidence summary
- Fragment 176-191 — Draft evidence summary
- Fragment 176-191 & CJC-1295 & Ipamorelin Blend — Draft combination overview
- Fragment 176-191 / Mod GRF 1-29 / ipamorelin blend — Draft combination overview
- GHK-Cu — Draft evidence summary
- GHK-Cu & KPV Blend — Draft combination overview
- GHRP-2 — Draft evidence summary
- GHRP-6 — Draft evidence summary
- GLOW (GHK-Cu / BPC-157 / TB-500) — Draft combination overview
- GLP 2 (TZ) (supplier code; identity unresolved) — Evidence summary pending
- GLP 3 (RT) (supplier code; identity unresolved) — Evidence summary pending
- GLP-2 (supplier code; identity unresolved) — Evidence summary pending
- GLP-3 (supplier code; identity unresolved) — Evidence summary pending
- Glutathione — Draft evidence summary
- Gonadorelin (GnRH) — Draft evidence summary
- Hexarelin — Draft evidence summary
- Humanin — Draft evidence summary
- IGF-1 LR3 — Draft evidence summary
- Illumineuro “Einstein” Peptide Blend (Semax, Selank, Pinealon, PE-22-28) — Draft combination overview
- Ipamorelin — Draft evidence summary
- Kisspeptin — Draft context overview
- Kisspeptin-10 — Draft evidence summary
- KLOW (GHK-Cu / BPC-157 / TB-500 / KPV) — Draft combination overview
- KPV — Draft evidence summary
- Lipopeptide — Draft context overview
- Liraglutide — Draft evidence summary
- Livagen — Draft evidence summary
- LL-37 — Draft evidence summary
- Matrixyl — Draft evidence summary
- Melanotan I / afamelanotide — Draft evidence summary
- Melanotan-2 — Draft evidence summary
- MGF — Draft evidence summary
- MGF IGF-1 EC — Draft context overview
- Mod GRF 1-29 & GHRP-2 Blend — Draft combination overview
- Mod GRF 1-29 & GHRP-6 Blend — Draft combination overview
- Mod GRF 1-29 (CJC without DAC) — Draft context overview
- Mod GRF 1-29 / hexarelin blend — Draft combination overview
- Mod GRF 1-29 / ipamorelin / GHRP-2 blend — Draft combination overview
- Mod GRF 1-29 / ipamorelin blend — Draft combination overview
- MOTS-c — Draft evidence summary
- N-Acetyl Epithalon — Draft context overview
- N-Acetyl Selank — Draft context overview
- N-Acetyl Semax — Draft context overview
- NAD+ — Draft evidence summary
- NAD+ / MOTS-C / 5-Amino-1MQ “Mitoprime” Blend — Draft combination overview
- Nonapeptide-1 — Draft evidence summary
- Ovagen — Draft evidence summary
- Oxytocin — Draft evidence summary
- P21 — Evidence summary pending
- Pal-AHK — Draft context overview
- Pal-GHK — Draft evidence summary
- Palmitoyl Tetrapeptide-7 — Draft evidence summary
- Pancragen — Draft evidence summary
- PE-22-28 — Draft evidence summary
- PEG-MGF — Draft context overview
- Pentapeptide-18 (Leuphasyl) — Draft evidence summary
- Pinealon — Draft evidence summary
- PNC-27 — Draft evidence summary
- Prostamax — Draft evidence summary
- PT-141 — Draft context overview
- PT-141 / Oxytocin — Draft combination overview
- PTD-DBM — Draft evidence summary
- Retatrutide — Draft evidence summary
- Selank — Draft evidence summary
- Selank (N-Acetyl Amidate) — Draft context overview
- Semaglutide — Draft evidence summary
- Semax — Draft evidence summary
- Semax & Selank Blend (N-Acetyl Amidate) — Draft combination overview
- Semax (N-Acetyl Amidate) — Draft context overview
- Semax / Selank — Draft combination overview
- Sermorelin — Draft context overview
- Sermorelin & GHRP-2 Blend — Draft combination overview
- Sermorelin & GHRP-6 & GHRP-2 Blend — Draft combination overview
- Sermorelin & GHRP-6 Blend — Draft combination overview
- Sermorelin & Ipamorelin Blend — Draft combination overview
- SNAP-8 — Draft evidence summary
- SS-31 — Draft context overview
- Syn-AKE — Draft evidence summary
- Syn-Coll (Palmitoyl Tripeptide-5) — Draft evidence summary
- TB-500 — Draft evidence summary
- TB-500 & BPC-157 & KPV “Coremend” Blend — Draft combination overview
- Tesamorelin — Draft evidence summary
- Tesamorelin / ipamorelin blend — Draft evidence summary
- Tesamorelin / Mod GRF 1-29 / ipamorelin blend — Draft combination overview
- Testagen — Draft evidence summary
- Thymagen — Draft context overview
- Thymalin — Draft evidence summary
- Thymosin Alpha-1 — Draft evidence summary
- Tirzepatide — Draft evidence summary
- TRH (thyrotropin-releasing hormone) — Draft context overview
- Tripeptide-29 — Draft context overview
- Triptorelin — Draft context overview
- Vesilut — Draft context overview
- Vesugen — Draft evidence summary
- Vialox (Pentapeptide-3V) — Draft evidence summary
- Vilon — Draft evidence summary
- VIP — Draft evidence summary
- Wolverine (BPC-157 / TB-500) — Draft combination overview